Early clinical experience with liarozole (Liazal(TM)) in patients with progressive prostate cancer

European Journal of Cancer

Volumn 34, Issue 4, 1998, Pages 469-475

  Denis, L ^a   Debruyne, F ^b   De Porre, P ^c   Bruynseels, J ^c  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Differentiation therapy; Liarozole; Metastasis; Prostate cancer; Retinoic acid metabolism

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALKALINE PHOSPHATASE; ANDROGEN; HYDROCORTISONE; LIAROZOLE; LIAROZOLE FUMARATE; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ARTICLE; ASTHENIA; BONE METASTASIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SKIN DISEASE; TREATMENT OUTCOME; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HORMONES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032033460     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10120-4     Document Type: Article

References (16)

1. 1. Oosterlinck W, Casselman J, Mattelaer J, Van Velthoven R, Kurjatkin O, Schulman C. Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. Eur Urol 1996, 30(4), 458-463.
2. 2. Dawson NA. Treatment of progressive metastatic prostate cancer. Oncology 1993, 7(5), 17-29.
3. 3. Small EJ, Srinivas S, Egan B, McMillan A, Rearden TP. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol 1996, 14(5), 1617-1625.
4. 4. Wouters W. Retinoid metabolism and its inhibition by liarozolefumarate. Ann Oncol 1994, 5(Suppl. 9), S45-S47.
5. 5. De Luca LM, Darwiche N, Jones CS, Scita G. Retinoids in differentiation and neoplasia. Scientific American 1995, 2(4), 28-37.
6. 6. Ong DE, Chytil F. Retinoic acid-binding protein in rat tissue. J Biol Chem 1975, 250(15), 6113-6117.
7. 7. Van Ginckel R, De Coster R, Wouters W, et al. Antitumoral effects of R75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats. Prostate 1990, 16(4), 313-323.
8. 8. Wouters W, De Coster R, Van Ginckel R, et al. Antitumoral activity of R075251 in experimental models. Proc Am Assoc Cancer Res 1990, 414 (abstract 31).
9. 9. Denis L. Liarozole-fumarate, a novel anti-tumoral drug: clinical update. International Symposium on Recent Advances in Diagnosis and Treatment of Prostate Cancer, Quebec City (Canada), 21-23 September 1995.
10. 10. Beynon LL, Chisholm GD. The stable state is not an objective response in hormone-escaped carcinoma of prostate. Br J Urol 1984, 56(6), 702-705.
11. 11. Iversen P, Rasmussen F, Asmussen C, et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer. DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol 1997, 157(3), 929-934.
12. 12. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993, 11(4), 607-615.
13. 13. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994, 12(10), 2005-2012.
14. 14. De Coster R, Caers I, Coene MC, Amery W, Beerens D, Haelterman C. Effects of high-dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients. Clin Endocrinol 1986, 24(6), 657-664.
15. 15. De Coster R, Mahler C, Denis L, et al. Effects of high-dose ketoconazole and dexamethasone on ACTH-stimulated adrenal steroidogenesis in orchiectomized prostatic cancer patients. Acta Endocrinol 1987, 115(2), 265-271.
16. 16. Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. J Urol 1984, 132(1), 61-63.